3,690
edits
No edit summary |
No edit summary |
||
Line 53: | Line 53: | ||
Delatte SJ, Hebra A, Tagge EP, Jackson S, Jacques K, Othersen HB Jr. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999 Jan; 34(1): 188-91; discussion 191-2. PMID: 10022169 | Delatte SJ, Hebra A, Tagge EP, Jackson S, Jacques K, Othersen HB Jr. Acute chest syndrome in the postoperative sickle cell patient. J Pediatr Surg. 1999 Jan; 34(1): 188-91; discussion 191-2. PMID: 10022169 | ||
Sohn E. Ease the Pain: The excruciating pain of sickle cell disease is difficult to prevent or treat. Researchers are working on new ways to provide relief. Sci Am 2024; 331(3): 94. | |||
Reardon S. New Treatments for Sickle Cell Disease: After years of little progress, new therapies to treat or even cure the disease are reaching patients. Sci Am 2024; 331(3): 85. | |||
Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Annals of internal medicine 2008; 148(2): 94-101. | |||
Smith WR, Scherer M. Sickle-Cell Pain: Advances in Epidemiology and Etiology. Hematology 2010; 2010(1): 409-15. | |||
Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: a daily diary study in children and adolescents. J Pediatr Hematol Oncol 2002; 24(8): 643-7. | |||
Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol 2009; 144(5): 782-8. | |||
Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005; 79(1): 17-25. | |||
Dampier CD, Telen MJ, Wun T, et al. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood 2023; 141(2): 168-79. | |||
Karimi M, Bahadoram M, Mafakher L, Rastegar M. Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease. Hematol Transfus Cell Ther 2024; 46(4): 387-92. | |||
"First Patient Begins Newly Approved Sickle Cell Gene Therapy." The New York Times, May 6, 2024. |